エストロゲン受容体陽性乳がん治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2024年～2030年

エストロゲン受容体陽性乳がん治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のエストロゲン受容体陽性乳がん治療市場は2030年までに337億米ドルに達すると予測され、2024年から2030年までのCAGRは7.89％で成長すると予測されています。

この市場には、このサブタイプの乳がんを標的とし管理するために特別に設計された様々な治療オプションが含まれます。

薬剤開発の革新はER+乳がん治療市場に大きな影響を与えています。新しい治療法には、新規アロマターゼ阻害薬、選択的エストロゲン受容体分解薬（SERD）、標的治療薬などがあります。例えば、2023年1月、FDAはESR1変異を有する転移性エストロゲン受容体陽性、HER2陰性乳がんに対する経口処方薬であるオーセルデュを認可し、個別化治療戦略へのシフトを強調しています。

製薬会社、バイオテクノロジー企業、研究機関の戦略的提携や協力関係は、ER+乳がん治療市場に大きな影響を与えます。例えば、2024年6月にメナリーニ・グループがインシリコ・メディシンと新規KAT6A阻害剤の開発でライセンシング契約を締結したことは、がん治療動向を前進させるための共同努力の傾向を強調しています。このようなパートナーシップは、薬剤開発の加速やより包括的な治療選択肢につながることが多く、ER+乳がんの治療状況全体を強化し、市場拡大に貢献しています。

エストロゲン受容体陽性乳がん治療市場レポート・ハイライト

• 治療別では、ホルモン療法が2023年に市場を席巻しました。その理由は、患者の転帰を改善する有効性、化学療法など他の治療法に比べて良好な副作用プロファイル、維持療法としての長期的適用性、ガイドラインによる強力な支持、より低侵襲な選択肢に対する患者の嗜好動向、費用対効果の高い治療を支持する経済的考慮、個別化医療アプローチを促進するバイオマーカー検査の進歩、このカテゴリーにおける新たな治療選択肢につながる継続的研究などです。
• エンドユーズ別では、病院が2023年に62.48％の最大売上シェアで市場を独占しました。その理由は、集学的チームによる包括的ケアの提供能力、臨床試験を含む先進治療へのアクセス、複雑なニーズを持つ高齢患者を支持する人口統計学的要因、保険適用とコスト効率に関する経済的考慮、患者の転帰を改善するための研究開発努力における極めて重要な役割などです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 エストロゲン受容体陽性乳がん治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• エストロゲン受容体陽性乳がん治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析

第4章 エストロゲン受容体陽性乳がん治療市場：治療別推定・動向分析

• 世界のエストロゲン受容体陽性乳がん治療市場：治療ダッシュボード
• 世界のエストロゲン受容体陽性乳がん治療市場：治療変動分析
• 世界のエストロゲン受容体陽性乳がん治療市場：治療別収益
• 化学療法
• 標的療法
• ホルモン療法
• 放射線治療
• その他

第5章 エストロゲン受容体陽性乳がん治療市場：最終用途別推定・動向分析

• 世界のエストロゲン受容体陽性乳がん治療市場：最終用途ダッシュボード
• 世界のエストロゲン受容体陽性乳がん治療市場：最終用途変動分析
• 世界のエストロゲン受容体陽性乳がん治療市場：最終用途別収益
• 病院
• 専門クリニック
• その他

第6章 エストロゲン受容体陽性乳がん治療市場：治療および最終用途別の地域別推定・動向分析

• 地域ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要企業の市場シェア分析、2023年
  • Radius Health, Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Lilly
  • EQRx, Inc.
  • Gilead Sciences, Inc.
  • Sermonix Pharmaceuticals
  • Tyme Limited
  • Genentech, Inc.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 4 North America Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 5 U.S. Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 6 U.S. Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 7 Canada Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 8 Canada Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 9 Mexico Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 10 Mexico Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 11 Europe Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 12 Europe Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 13 Europe Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 14 Germany Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 15 Germany Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 16 UK Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 17 UK Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 18 France Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 19 France Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 20 Italy Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 21 Italy Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 22 Spain Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 23 Spain Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 24 Denmark Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 25 Denmark Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 26 Sweden Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 27 Sweden Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 28 Norway Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 29 Norway Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 30 Asia Pacific Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 31 Asia Pacific Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 32 Asia Pacific Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 33 China Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 34 China Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 35 Japan Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 36 Japan Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 37 India Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 38 India Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 39 South Korea Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 40 South Korea Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 41 Australia Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 42 Australia Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 43 Thailand Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 44 Thailand Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 45 Latin America Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 46 Latin America Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 47 Latin America Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 48 Brazil Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 49 Brazil Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 50 Argentina Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 51 Argentina Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 52 MEA Estrogen receptor positive breast cancer treatment market, by region, 2018 - 2030 (USD Million)
• Table 53 MEA Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 54 MEA Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 55 South Africa Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 56 South Africa Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 57 Saudi Arabia Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 58 Saudi Arabia Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 59 UAE Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 60 UAE Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)
• Table 61 Kuwait Estrogen receptor positive breast cancer treatment market, by treatment, 2018 - 2030 (USD Million)
• Table 62 Kuwait Estrogen receptor positive breast cancer treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Market research approaches
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Estrogen receptor positive breast cancer treatment market: market outlook
• Fig. 7 Estrogen receptor positive breast cancer treatment competitive insights
• Fig. 8 Parent market outlook
• Fig. 9 Related/ancillary market outlook
• Fig. 10 Estrogen receptor positive breast cancer treatment market driver impact
• Fig. 11 Estrogen receptor positive breast cancer treatment market restraint impact
• Fig. 12 Estrogen receptor positive breast cancer treatment market: Treatment movement analysis
• Fig. 13 Estrogen receptor positive breast cancer treatment market: Treatment outlook and key takeaways
• Fig. 14 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 15 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 16 Hormonal therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 17 Radiation therapy market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 18 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 19 Estrogen receptor positive breast cancer treatment market: End Use movement analysis
• Fig. 20 Estrogen receptor positive breast cancer treatment market: End Use outlook and key takeaways
• Fig. 21 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Specialty Clinics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Other market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Global Estrogen receptor positive breast cancer treatment market: Regional movement analysis
• Fig. 25 Global Estrogen receptor positive breast cancer treatment market: Regional outlook and key takeaways
• Fig. 26 Global Estrogen receptor positive breast cancer treatment market share and leading players
• Fig. 27 North America, by country
• Fig. 28 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 29 U.S. key country dynamics
• Fig. 30 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Canada key country dynamics
• Fig. 32 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Mexico key country dynamics
• Fig. 34 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 UK key country dynamics
• Fig. 37 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Germany key country dynamics
• Fig. 39 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 France key country dynamics
• Fig. 41 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Italy key country dynamics
• Fig. 43 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 Spain key country dynamics
• Fig. 45 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Denmark key country dynamics
• Fig. 47 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 Sweden key country dynamics
• Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Norway key country dynamics
• Fig. 51 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 China key country dynamics
• Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 Japan key country dynamics
• Fig. 56 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 India key country dynamics
• Fig. 58 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Thailand key country dynamics
• Fig. 60 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 South Korea key country dynamics
• Fig. 62 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Australia key country dynamics
• Fig. 64 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Brazil key country dynamics
• Fig. 67 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Argentina key country dynamics
• Fig. 69 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 South Africa key country dynamics
• Fig. 72 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 73 Saudi Arabia key country dynamics
• Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 75 UAE key country dynamics
• Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 77 Kuwait key country dynamics
• Fig. 78 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 Market share of key market players- Estrogen receptor positive breast cancer treatment market

Estrogen Receptor Positive Breast Cancer Treatment Market Growth & Trends:

The global estrogen receptor positive breast cancer treatment market is anticipated to reach USD 33.7 billion by 2030 and is projected to grow at a CAGR of 7.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market includes a variety of therapeutic options specifically designed to target and manage this subtype of breast cancer.

Innovations in drug development are significantly impacting the ER+ breast cancer treatment market. New therapies include novel aromatase inhibitors, selective estrogen receptor degraders (SERDs), and targeted treatments. For instance, in January 2023, the FDA authorized Orserdu, an oral prescription for metastatic estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation, underscoring a shift towards personalized treatment strategies.

Strategic collaborations and partnerships between pharmaceutical companies, biotechnology firms, and research institutions significantly impact the market for ER+ breast cancer treatment. For instance, in June 2024, Menarini Group's licensing agreement with Insilico Medicine to develop a new KAT6A inhibitor underscores the trend toward collaborative efforts to advance oncology treatments. These partnerships often lead to accelerated drug development and more comprehensive treatment options, enhancing the overall treatment landscape for ER+ breast cancer and contributing to market expansion.

Estrogen Receptor Positive Breast Cancer Treatment Market Report Highlights:

• Based on treatment, hormonal therapy dominated the market in 2023 due to its efficacy in improving patient outcomes, favorable side effect profiles compared with other modalities such as chemotherapy, long-term applicability as maintenance therapy, strong guideline support, patient preference trends towards less invasive options, economic considerations favoring cost-effective treatments, advancements in biomarker testing facilitating personalized medicine approaches, and continuous research leading to new therapeutic options within this category.
• Based on end use, hospitals dominated the market with the largest revenue share of 62.48% in 2023 due to their ability to provide comprehensive care through multidisciplinary teams, access to advanced treatments including clinical trials, demographic factors favoring older patients with complex needs, economic considerations regarding insurance coverage and cost efficiency, and their pivotal role in R&D efforts to improve patient outcomes.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Treatment
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Estrogen Receptor Positive Breast Cancer Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. High incidence and prevalence of ER+ breast cancer
    • 3.2.1.2. Availability of endocrine therapies targeting ER
    • 3.2.1.3. Increasing adoption of targeted therapies
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited treatment options for resistant cases
    • 3.2.2.2. High costs associated with advanced therapies
• 3.3. Estrogen Receptor Positive Breast Cancer Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Dashboard
• 4.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: Treatment Movement Analysis
• 4.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market by Treatment, Revenue
• 4.4. Chemotherapy
  • 4.4.1. Chemotherapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Targeted Therapy
  • 4.5.1. Targeted therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Hormonal Therapy
  • 4.6.1. Hormonal therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Radiation Therapy
  • 4.7.1. Radiation therapy market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Other
  • 4.8.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Dashboard
• 5.2. Global Estrogen Receptor Positive Breast Cancer Treatment Market: End Use Movement Analysis
• 5.3. Global Estrogen Receptor Positive Breast Cancer Treatment Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Specialty Clinics
  • 5.5.1. Specialty clinics market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Other
  • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Estrogen Receptor Positive Breast Cancer Treatment Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Thailand
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Company/Competition Categorization
• 7.2. Vendor Landscape
  • 7.2.1. List of key distributors and channel partners
  • 7.2.2. Key company market share analysis, 2023
  • 7.2.3. Radius Health, Inc.
    • 7.2.3.1. Company overview
    • 7.2.3.2. Financial performance
    • 7.2.3.3. Product benchmarking
    • 7.2.3.4. Strategic initiatives
  • 7.2.4. Sanofi
    • 7.2.4.1. Company overview
    • 7.2.4.2. Financial performance
    • 7.2.4.3. Product benchmarking
    • 7.2.4.4. Strategic initiatives
  • 7.2.5. F. Hoffmann-La Roche Ltd
    • 7.2.5.1. Company overview
    • 7.2.5.2. Financial performance
    • 7.2.5.3. Product benchmarking
    • 7.2.5.4. Strategic initiatives
  • 7.2.6. AstraZeneca
    • 7.2.6.1. Company overview
    • 7.2.6.2. Financial performance
    • 7.2.6.3. Product benchmarking
    • 7.2.6.4. Strategic initiatives
  • 7.2.7. Lilly
    • 7.2.7.1. Company overview
    • 7.2.7.2. Financial performance
    • 7.2.7.3. Product benchmarking
    • 7.2.7.4. Strategic initiatives
  • 7.2.8. EQRx, Inc.
    • 7.2.8.1. Company overview
    • 7.2.8.2. Financial performance
    • 7.2.8.3. Product benchmarking
    • 7.2.8.4. Strategic initiatives
  • 7.2.9. Gilead Sciences, Inc.
    • 7.2.9.1. Company overview
    • 7.2.9.2. Financial performance
    • 7.2.9.3. Product benchmarking
    • 7.2.9.4. Strategic initiatives
  • 7.2.10. Sermonix Pharmaceuticals
    • 7.2.10.1. Company overview
    • 7.2.10.2. Financial performance
    • 7.2.10.3. Product benchmarking
    • 7.2.10.4. Strategic initiatives
  • 7.2.11. Tyme Limited
    • 7.2.11.1. Company overview
    • 7.2.11.2. Financial performance
    • 7.2.11.3. Product benchmarking
    • 7.2.11.4. Strategic initiatives
  • 7.2.12. Genentech, Inc.
    • 7.2.12.1. Company overview
    • 7.2.12.2. Financial performance
    • 7.2.12.3. Product benchmarking
    • 7.2.12.4. Strategic initiatives